Key Points Non-GAAP earnings per share and GAAP revenue both surpassed analyst estimates, with adjusted funds from operations (AFFO) also showing modest growth. Combined portfolio net operating income ...

Glucagon injection salesdeclined 25% to $20.6 million in Q2 2025, driven by increased competition and a market shift toward ...

Q2 2025 Management View Scott L. Thompson, Chairman, President and CEO, stated that "Somnigroup delivered another quarter of solid performance, driven by disciplined execution and progress in our ...